{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:14:48Z","timestamp":1790252088303,"version":"4.1.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xkme.2024.100943","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T12:34:18Z","timestamp":1734093258000},"page":"100943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review"],"prefix":"10.1016","volume":"7","author":[{"given":"Porntep","family":"Amornritvanich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1002-8536","authenticated-orcid":false,"given":"Thunyarat","family":"Anothaisintawee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarin","family":"Thakkinstian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10225","key":"10.1016\/j.xkme.2024.100943_bib1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.xkme.2024.100943_bib2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.kint.2016.09.010","article-title":"Management of patients with diabetes and CKD: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"90","author":"Perkovic","year":"2016","journal-title":"Kidney Int"},{"issue":"13","key":"10.1016\/j.xkme.2024.100943_bib3","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.xkme.2024.100943_bib4","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1471-2369-12-38","article-title":"Association of blood pressure with decline in renal function and time until the start of renal replacement therapy in pre-dialysis patients: a cohort study","volume":"12","author":"de Goeij","year":"2011","journal-title":"BMC Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100943_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD","volume":"62","author":"Taler","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.xkme.2024.100943_bib6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.xkme.2024.100943_bib7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100943_bib8","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"issue":"36","key":"10.1016\/j.xkme.2024.100943_bib9","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"23","key":"10.1016\/j.xkme.2024.100943_bib10","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.xkme.2024.100943_bib11","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11906-022-01177-6","article-title":"The time to reconsider mineralocorticoid receptor blocking strategy: arrival of nonsteroidal mineralocorticoid receptor blockers","volume":"24","author":"Tezuka","year":"2022","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5582\/irdr.2020.01008","article-title":"The cardiovascular outcomes of finerenone in patients with chronic kidney disease and type 2 diabetes: A meta-analysis of randomized clinical trials","volume":"11","author":"Abdelazeem","year":"2022","journal-title":"Intractable Rare Dis Res"},{"issue":"12","key":"10.1016\/j.xkme.2024.100943_bib13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1007\/s00228-022-03408-w","article-title":"Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials","volume":"78","author":"Bao","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xkme.2024.100943_bib14","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4103\/ijem.ijem_376_21","article-title":"Efficacy and safety of novel non-steroidal mineralocorticoid receptor antagonist finerenone in the management of diabetic kidney disease: A meta-analysis","volume":"26","author":"Dutta","year":"2022","journal-title":"Indian J Endocrinol Metab"},{"key":"10.1016\/j.xkme.2024.100943_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1078686","article-title":"Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis. Review","volume":"13","author":"Li","year":"2022","journal-title":"Front Endocrinol"},{"issue":"6","key":"10.1016\/j.xkme.2024.100943_bib16","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1111\/dom.15009","volume":"25","author":"Nguyen","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.xkme.2024.100943_bib17","article-title":"Network meta-analysis on the effects of SGLT2 inhibitors versus finerenone on cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.xkme.2024.100943_bib18","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.21037\/apm-21-763","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis","volume":"10","author":"Fu","year":"2021","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.xkme.2024.100943_bib19","article-title":"Efficacy and safety of finerenone in chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xkme.2024.100943_bib20","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes: a systematic review incorporating an indirect comparisons meta-analysis","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xkme.2024.100943_bib21","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.xkme.2024.100943_bib22","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J\u00a0Hypertens"},{"issue":"6","key":"10.1016\/j.xkme.2024.100943_bib23","doi-asserted-by":"crossref","first-page":"916","DOI":"10.2215\/CJN.15841020","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists in kidney failure patients treated with dialysis: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2024.100943_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110210","article-title":"Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis","volume":"195","author":"Chen","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.xkme.2024.100943_bib25","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.xkme.2024.100943_bib27","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejim.2023.05.038","article-title":"Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease. Article","volume":"113","author":"Ding","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.xkme.2024.100943_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1114894","article-title":"Finerenone in type 2 diabetes and renal outcomes: A random-effects model meta-analysis","volume":"14","author":"Ghosal","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.xkme.2024.100943_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.823530","article-title":"Association of mineralocorticoid receptor antagonists with the mortality and cardiovascular effects in dialysis patients: a meta-analysis","volume":"13","author":"Gou","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100943_bib30","article-title":"Aldosterone antagonists for people with chronic kidney disease requiring dialysis","volume":"2","author":"Hasegawa","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.xkme.2024.100943_bib31","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","article-title":"Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis","volume":"37","author":"Hou","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.xkme.2024.100943_bib32","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/6683987","article-title":"Efficacy and safety of eplerenone for treating chronic kidney disease: a meta-analysis","volume":"2023","author":"Hu","year":"2023","journal-title":"Int J Hypertens"},{"issue":"3","key":"10.1016\/j.xkme.2024.100943_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0265642","article-title":"Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis","volume":"17","author":"Hu","year":"2022","journal-title":"PLOS ONE"},{"key":"10.1016\/j.xkme.2024.100943_bib34","article-title":"Safety and efficacy of spironolactone in dialysis-dependent patients: meta-analysis of randomized controlled trials","volume":"9","author":"Liu","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"5","key":"10.1016\/j.xkme.2024.100943_bib35","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/dom.14976","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors, mineralocorticoid receptor antagonists, and their combination on albuminuria in diabetic patients","volume":"25","author":"Morita","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"10.1016\/j.xkme.2024.100943_bib36","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.xkme.2024.100943_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/1470320315575849","article-title":"Cardiovascular actions of mineralocorticoid receptor antagonists in\u00a0patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials","volume":"16","author":"Ng","year":"2015","journal-title":"J\u00a0Renin Angiotensin Aldosterone Syst"},{"issue":"4","key":"10.1016\/j.xkme.2024.100943_bib38","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2016.04.011","article-title":"The safety and efficacy of mineralocorticoid receptor antagonists in patients who require dialysis: a systematic review and meta-analysis","volume":"68","author":"Quach","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.xkme.2024.100943_bib39","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jdi.12629","article-title":"Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy","volume":"8","author":"Sun","year":"2017","journal-title":"J\u00a0Diabetes Investig"},{"issue":"2","key":"10.1016\/j.xkme.2024.100943_bib40","first-page":"794","article-title":"Effects of spironolactone on cardiovascular outcomes in chronic kidney disease and end-stage renal disease patients. Article","volume":"9","author":"Sun","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.xkme.2024.100943_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110161","article-title":"Cardiovascular and kidney outcomes of combination therapy with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis","volume":"194","author":"Tsukamoto","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.xkme.2024.100943_bib42","article-title":"Network meta-analysis of mineralocorticoid receptor antagonists for diabetic kidney disease","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.xkme.2024.100943_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110592","article-title":"Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials","author":"Yang","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib44","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/FJC.0000000000001364","article-title":"Efficacy and safety of finerenone for prevention of cardiovascular events in type 2 diabetes mellitus with chronic kidney disease: a meta-analysis of randomized controlled trials","volume":"81","author":"Yang","year":"2023","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"11","key":"10.1016\/j.xkme.2024.100943_bib45","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/dom.14801","volume":"24","author":"Yang","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.xkme.2024.100943_bib46","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2147\/DDDT.S189454","article-title":"Safety evaluation and cardiovascular effect of additional use of spironolactone in hemodialysis patients: A meta-analysis. Article","volume":"13","author":"Zeng","year":"2019","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12933-022-01676-5","article-title":"Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"21","author":"Zhang","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib48","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13098-022-00929-3","article-title":"Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"14","author":"Zhang","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"4","key":"10.1016\/j.xkme.2024.100943_bib49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000521908","article-title":"Meta-analysis of the efficacy and safety of finerenone in diabetic kidney disease","volume":"47","author":"Zheng","year":"2022","journal-title":"Kidney Blood Press Res"},{"issue":"8","key":"10.1016\/j.xkme.2024.100943_bib50","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024882","article-title":"The safety and efficacy of low-dose mineralocorticoid receptor antagonists in dialysis patients: A meta-analysis","volume":"100","author":"Zhu","year":"2021","journal-title":"Med (Baltim)"},{"issue":"5","key":"10.1016\/j.xkme.2024.100943_bib51","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s11255-022-03432-w","article-title":"Effect of finerenone on cardiovascular events in kidney disease and\/or diabetes: a meta analysis of randomized control trials","volume":"55","author":"Zhu","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.xkme.2024.100943_bib52","doi-asserted-by":"crossref","DOI":"10.1111\/ijcp.13413","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists with ACEI\/ARB treatment for diabetic nephropathy: A meta-analysis","author":"Zuo","year":"2019","journal-title":"Int J Clin Pract"},{"issue":"13","key":"10.1016\/j.xkme.2024.100943_bib53","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1111\/bph.15734","article-title":"The mineralocorticoid receptor in chronic kidney disease","volume":"179","author":"Barrera-Chimal","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ajh\/hpaa137","article-title":"Aldosterone, inflammation, immune system, and hypertension","volume":"34","author":"Ferreira","year":"2021","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib55","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.kisu.2021.11.006","article-title":"The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis","volume":"12","author":"Luther","year":"2022","journal-title":"Kidney Int Suppl (2011)"},{"issue":"5","key":"10.1016\/j.xkme.2024.100943_bib56","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.xkme.2024.100943_bib57","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11906-013-0414-8","article-title":"Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles","volume":"16","author":"Danjuma","year":"2014","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"10.1016\/j.xkme.2024.100943_bib58","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.xkme.2024.100943_bib59","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.xkme.2024.100943_bib60","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"6","key":"10.1016\/j.xkme.2024.100943_bib62","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1056\/NEJMra1503102","article-title":"Electrolyte and acid-base disturbances in patients with diabetes mellitus. Review","volume":"373","author":"Palmer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2024.100943_bib63","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.xkme.2024.100943_bib64","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.ajkd.2021.02.324","article-title":"Finerenone\u2014A new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease","volume":"78","author":"Sridhar","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.xkme.2024.100943_bib65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"10.1016\/j.xkme.2024.100943_bib67","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.xkme.2024.100943_bib68","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/j.1463-1326.2007.00730.x","article-title":"Eplerenone improves prognosis in postmyocardial infarction diabetic patients with heart failure: results from EPHESUS","volume":"10","author":"O'Keefe","year":"2008","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.xkme.2024.100943_bib69","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma\u00a0aldosterone concentrations in chronic renal disease","volume":"21","author":"Hen\u00e9","year":"1982","journal-title":"Kidney Int"},{"issue":"1-3","key":"10.1016\/j.xkme.2024.100943_bib70","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1159\/000441262","article-title":"Mineralocorticoid receptor antagonists in end-stage renal disease: efficacy and safety","volume":"41","author":"Bomback","year":"2016","journal-title":"Blood Purif"},{"issue":"4","key":"10.1016\/j.xkme.2024.100943_bib71","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/j.1552-4604.1989.tb03339.x","article-title":"Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites","volume":"29","author":"Gardiner","year":"1989","journal-title":"J\u00a0Clin Pharmacol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524001547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524001547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T20:23:17Z","timestamp":1740860597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059524001547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2590059524001547"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100943","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100943"}}